FemBloc Permanent Contraceptive System

Description: A degradable biopolymer is sent through a catheter-based delivery system placed in the uterus to permanently block the fallopian tubes after several weeks.

Product Details

Duration: Permanent

Status Details

Status Details:
  • IDE approval granted by FDA in 2016 for U.S. prospective, multi-center clinical trial of FemBloc that began in 2017.

Additional Information

  • Femasys website: http://www.femasys.com/

  • ClinicalTrials.gov Identified NCT03067272

  • ClinicalTrials.gov Identified NCT03433911

Vertical Tabs